About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $35 ...

Millions of obese Americans would be eligible to have drugs like Wegovy or Zepbound covered by Medicare or Medicaid under the ...

The White House said it's moving to make the federal health insurance plans pay for anti-obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound for people who are obese, even if they don ...

The Biden administration proposed a rule to let Medicare and Medicaid cover obesity drugs like Ozempic. Millions would ...

Should employers, patients or insurers cover the $411 billion annual cost for GLP-1 drugs? U.S. healthcare industry grapples with this question as demand grows.

CMS proposes changes to Medicare and Medicaid to cover weight-loss drugs, recognizing obesity as a disease. This could expand ...

The plans from the Department of Health and Human Services come on the heels of criticism Ozempic and other weight loss medications received by RFK Jr.

U.S. President Joe Biden on Tuesday proposed expanding coverage of anti-obesity drugs, like Novo Nordisk's Wegovy, for more ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

Outgoing US President Joe Biden proposed Tuesday to give millions more Americans access to weight loss drugs -- but Donald ...

Amgen's phase 2 data disappointed, but its obesity pipeline still holds potential. See why AMGN stock is appealing even without the full upside from MariTide.